Weekly Recap | BioNTech SE -6.78%, CEO sells into weakness
I'm LongbridgeAI, I can summarize articles.BioNTech (BNTX) closed the week at $96.73, down 6.78% over the five-session stretch. Against the S&P 500’s 0.8% decline, the stock lagged by roughly 5.98 percentage points. The move was a fade: after opening at $100.24 on Tuesday and touching an intraday high of $101.33, the price slid through the week and settled at $96.73 on Friday, with a weekly range of 5.47%.
The Week
BioNTech (BNTX) closed the week at $96.73, down 6.78% over the five-session stretch. Against the S&P 500’s 0.8% decline, the stock lagged by roughly 5.98 percentage points. The move was a fade: after opening at $100.24 on Tuesday and touching an intraday high of $101.33, the price slid through the week and settled at $96.73 on Friday, with a weekly range of 5.47%.
Key Events
The most direct story was insider selling. On 9 September, CEO Ugur Sahin sold ordinary shares worth about $7.86 million; a later filing showed Uğur Şahin offloading another 20,500 shares for $1.97 million. Alongside that, commentary circulated on how past trial terminations have reshaped BioNTech’s investment narrative. The rest of the week’s news was mostly sector-level divergence and routine positioning moves, less tied to company fundamentals.
Analyst Ratings
Twenty brokers cover BioNTech: 13 rate it buy, 1 overweight, 5 hold, 1 underweight, and 0 sell. The consensus rating is buy, with a target price of $119.08, about 23.1% above the last close of $96.73. Target estimates range from $75.76 to $144.54, showing wide dispersion. Within its industry, BioNTech ranks 23rd out of 506 biotechnology names.
The Week Ahead
The macro calendar is busy. On 15 September the Empire State manufacturing index lands, and on 16 September come retail sales, retail sales ex-autos, import prices, the NAHB housing market index, and EIA crude inventories. If macro data stirs biotech sentiment, BNTX could move in sympathy. On the company side, the next earnings report is Q3 FY2026, expected on 3 November.
In Short
BioNTech fell this week while insider selling grabbed attention, yet the broker community still skews buy and the consensus target sits about 23% above spot. In the latest session, large-lot money was a net seller while small-lot flow skewed net buying. Valuations show negative earnings per share and a price-to-book of 1.2x. What matters next is whether the selling continues and whether the Q3 report in November can anchor a re-rating.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.